Next-Generation JAK Inhibition for Patients With Myelofibrosis

Cytopenias and Symptoms Prompt Initiation of JAK Inhibitors in MF

During a Case-Based Roundtable® event, Gabriela S. Hobbs, MD, surveyed physicians on the disease features that are most challenging in primary myelofibrosis in the first article of a 2-part series.

Newer JAK Inhibitors Aid in Cytopenia Management for High-Risk Myelofibrosis

During a Case-Based Roundtable® event, Kristen Pettit, MD, discussed the use of pacritinib and momelotinib in cytopenic myelofibrosis in the second article of a 2-part series.

Challenging Disease Features of Myelofibrosis Lead to Use of JAK Inhibitors

During a Case-Based Roundtable® event, Kristen Pettit, MD, moderated a discussion on which disease features of myelofibrosis are most challenging and when to use JAK inhibitors in the first article of a 2-part series.

Understanding the Deep Response to Pacritinib in Myelofibrosis

During a Case-Based Roundtable® event, John Mascarenhas, MD, discussed the deep response with pacritinib and its adverse event profile for patients with myelofibrosis in the second article of a 2-part series.

How the PERSIST-2 Results Show The Benefit of Pacritinib in MF

During a Case-Based Roundtable® event, John Mascarenhas, MD, discussed the efficacy data behind the use of pacritinib in patients with myelofibrosis in the first article of a 2-part series.

Challenges of Interpreting JAK Inhibitor Data for Real-World Myelofibrosis Care

During a Targeted Oncology™ Case-Based Roundtable™ event, Bart Scott, MD, discussed the importance of overall survival data in JAK inhibitor trials and how to transition between agents. This is the second of 2 articles based on this event.

Pacritinib Shows Transfusion Independence Benefits in Myelofibrosis

During a Targeted Oncology™ Case-Based Roundtable™ event, Bart Scott, MD, discussed JAK inhibitor options and the data from the PERSIST-2 trial of pacritinib. This is the first of 2 articles based on this event.

Evolving Roles of JAK Inhibitors in Cytopenic Myelofibrosis

During a Targeted Oncology™ Case-Based Roundtable™ event, Naveen Pemmaraju, MD, discussed the development of Janus kinase inhibitors and how newer therapies meet needs of patients with cytopenic myelofibrosis.

Goals of Managing Cytopenic Myelofibrosis in Younger Patients

During a Targeted Oncology™ Case-Based Roundtable™ event, Naveen Pemmaraju, MD, and participants discussed the role of JAK inhibitors in managing myelofibrosis particularly in younger patients who may receive allogeneic stem cell transplant. This is the first of 2 articles based on this event.

Management of Adverse Events Related to Pacritinib in Myelofibrosis

Ashwin Kishtagari, MD, discusses the adverse events of pacritinib for patients with primary myelofibrosis and low platelet counts.

Pacritinib Improves Spleen Volume and Symptoms in Myelofibrosis

Ashwin Kishtagari, MD, discusses the PERSIST-2 trial of pacritinib for patients with primary myelofibrosis and low platelet counts.

When to Stop or Switch JAK Inhibitor Therapy in Myelofibrosis

Introducing Pacritinib into Treatment Plans for Myelofibrosis

During a Targeted Oncology case-based roundtable event, Jeanne M. Palmer, MD, discussed with participants how the approval of pacritinib for patients with myelofibrosis affects their treatment approach.

Reactions to the Latest Data on JAK Inhibition for Myelofibrosis

During a live virtual event, John O. Mascarenhas, MD, discussed with participants the data supporting the use of pacritinib for patients with myelofibrosis. This is the second of 2 articles based on this event.

Pacritinib Shows Spleen and Symptom Response in Myelofibrosis With Low Platelets

During a live virtual event, John O. Mascarenhas, MD, discussed the PERSIST-1 and PERSIST-2 trials of pacritinib for patients with myelofibrosis with lower platelet counts.

Pacritinib Shows Tolerable Safety Profile for Thrombocytopenic Myelofibrosis

Srdan Verstovsek, MD, PhD, discusses the tolerability of pacritinib for patients with myelofibrosis.